Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
31 5월 2023 - 7:30PM
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage
biotechnology company developing treatments for serious
degenerative genetic diseases, today reported that management will
present at the 2023 Jefferies Healthcare Conference on Wednesday,
June 7, 2023 at 3:30 p.m. ET in NYC.
A live webcast will be available in the investor section of the
company's website at www.designtx.com. The webcast will be archived
for 30 days following the presentation.
About Design TherapeuticsDesign Therapeutics is
a clinical-stage biotechnology company developing a new class of
therapies based on its platform of GeneTAC™ gene targeted chimera
small molecules. The company’s GeneTAC™ molecules are designed to
either dial up or dial down the expression of a specific
disease-causing gene to address the underlying cause of disease.
Design is currently evaluating its lead GeneTAC™ small molecule,
DT-216, in an ongoing Phase 1 clinical trial in patients with
Friedreich ataxia. The company is also advancing programs in Fuchs
endothelial corneal dystrophy and myotonic dystrophy type-1.
Discovery efforts for multiple other serious degenerative disorders
caused by nucleotide repeat expansions are also underway, including
for fragile X syndrome, spinocerebellar ataxias, Huntington
disease, spinobulbar muscular atrophy, and C9orf72-amyotrophic
lateral sclerosis/frontotemporal dementia. For more information,
please visit designtx.com.
Contact:Investors:Chelcie ListerTHRUST
Strategic Communicationschelcie@thrustsc.com
Design Therapeutics (NASDAQ:DSGN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Design Therapeutics (NASDAQ:DSGN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024